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Head and neck squamous cell carcinomaHead and neck squamous cell carcinoma (HNSCC) represent 95% of head and neck cancer with an inci-
dence of over half a million people globally. The prognosis for patients with recurrent or metastatic
HNSCC is generally poor with low 5-year survival rates despite treatment advances over the past few dec-
ades. Consequently, it is essential to search for new biomarkers and effective therapy options to optimize
HNSCC treatment. Epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of
tumours. EGFR has become one of most common targets for new therapies being investigated in
HNSCC. In this way, multiple therapies targeting EGFR in HNSCC have been tested but response rates
are still low especially in the recurrent or metastatic setting. This has been attributed to mechanisms
of resistance to EGFR-targeted therapies. Afatinib, an oral small molecule ErbB Family Blocker that irre-
versibly binds to ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4), is being investigated in HNSCC treat-
ment with encouraging phase II results and several ongoing phase III trials. Results of these trials will
help to understand the place of afatinib in the HNSCC treatment armamentarium.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Head and neck squamous cell carcinoma (HNSCC), the sixth
most common cancer globally, affects 600,000 new patients each
year and is associated with high morbidity [1]. The most common
sites for HNSCC are the pharynx/larynx, tongue and mouth [2].
Despite new advances in therapy, overall long-term survival
remains low and approximately 40–50% of patients with advanced
disease die within 5 years [3–7].
HNSCC is categorised into three general stages: early-stage
(stage I/II), locally-regionally advanced (stage III/IV) and recur-
rent/metastatic disease [8]. More than two-thirds of patients pre-
sent with locoregionally advanced disease, and over the last
three decades, multimodal therapy with surgery, radiation therapy
and pharmacotherapy has been the standard treatment for these
patients [3,8]. Cisplatin-based chemoradiation is the standard of
care for the deﬁnitive and adjuvant treatment of locoregionally
advanced disease [8]. However, these therapies are often
aggressive [9] and carry considerable side effects. Many patients(10–30%) with locoregionally advanced HNSCC develop metastasis
[10], most commonly in the lungs [11]. Indeed, more than 50% of
patients who die from HNSCC have experienced a failure of locore-
gional control of the tumour as it begins to invade surrounding tis-
sues and eventually metastasises [9]. Approximately 90% of those
patients with metastases also have locoregional failure. As such,
locoregional control – that is, prevention of tumour growth – is
essential in order to improve patient prognosis [9].
Treatment options for recurrent/metastatic HNSCC patients are
limited, and palliative platinum-based chemotherapy is the stan-
dard of care [8] in conjunction with best supportive care. The
choice of a systemic regimen depends on the patients´ prior treat-
ment and whether the patient has previously received systemic
therapy for metastatic or incurable locoregional disease. High
number of chemotherapeutic agents are used, [8] including plat-
inum compounds (cisplatin, carboplatin) [12], taxanes (docetaxel,
paclitaxel) [13]; methotrexate [13,14] and 5-ﬂuorouracil [15].
Platinum-based combination regimens do appear to have
improved the objective response rate compared with single-agent
chemotherapy in these patients, although no improvement in over-
all survival has been demonstrated. For those patients who do not
respond or progress during palliative treatment there is no effec-
tive alternative chemotherapy [8].
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Molecular research on HNSCC is focused on identifying the
genetic proﬁle of primary tumours with the highest probability
of metastasis. However, similar aberrations were identiﬁed in both
primary tumours and lymph-node metastases: 3q (90%), 8q (65%),
1q (50%), 5p (43%), 2q (41%) and 11q (41%) and deletions 3p (57%),
1p (5%), 4p (48%), 13q (48%), 11q (41%) and 10q (37%) (Table 1).
Unfortunately, no combination of chromosomal aberrations was
associated with metastatic progression in HNSCC [16].
Multiple biomarkers have been described in HNSCC based on
protein expression level [4]. Bcl-2 expression is related to outcome
following chemoradiation in HNSCC [17]. Interestingly, Ki-67
expression was associated with radiosensitivity in glottic cancer,
while in laryngeal HNSCC, Ki-67 expression has been shown to cor-
relate with advanced stage and neoplasm progression [18,19].
Genome-wide sequencing and copy number analysis have clar-
iﬁed commonly mutated genes in HNSCC [20–22]. Some have high-
er therapeutic potential, such as epidermal growth factor receptor
(EGFR), ﬁbroblast growth factor receptor (FGFR), hepatocyte
growth factor receptor (c-MET), cyclin D1 (CCND1) or phospho-
inositide 3-kinase (PI3K) [23]. EGFR overexpression has been
observed in approximately 90% of HNSCC tumours [24], and this
overexpression is associated with poor prognosis and resistance
to chemotherapy and radiation therapy [7,25]. Mechanisms that
may contribute to the increased levels of EGFR observed include
dysregulated p53 [26] and EGFR ampliﬁcation [27]. Otherwise,
EGFR expression analysis by immunohistochemistry has not been
applied in clinical practice. Therefore, presence of mutations and
detection of polymorphisms in EGFR is more extended [28].
FGFR synthesises for a transmembrane tyrosine kinase receptor
and triggers signalling pathways including MAPK, PI3K, p38, JNK or
STAT [23]. In lung squamous cell carcinoma which has similar
molecular characteristics to HNSCC, ampliﬁcation of variant 1 of
FGFR (FGFR1) and c-MYC confers susceptibility to FGFR inhibitorsTable 1
Genetic aberrations of HNSCC (adapted from Patmore et al. [16]).
Location Gain/deletion Percent PT
3q26-27 Gain 78
3p25-pter Deletion 52
5q34-qter Deletion 52
1p34.2-pter Deletion 43
5p15.1-pter Gain 43
11q13.3-13.5 Gain 39
11q23.3 Deletion 39
12p12.3-13.1 Gain 39
2q31 Gain 39
3q24 Gain 39
8q21.3 Gain 39
8q23 Gain 39
18p11.31-pter Gain 35
3p14p1-3 Deletion 35
6q12 Gain 35
10q26.1-qter Deletion 30
13q31 Deletion 30
4p16 Deletion 30
8p22 Deletion 30
1q31 Gain 26
7q31.1-3 Gain 26
12q22 Gain 22
1q21.2 Gain 22
19p13.3-pter Deletion 17
4q26 Gain 17
4q34 Deletion 17
6q22 Gain 17
5q13 Deletion 13
9p24 Deletion 13
13q22 Gain 9
PT = primary tumour.[29]. Some studies concerning HNSCC showed decreased cell pro-
liferation and invasion using inhibitors of FGFR1 [30,31].
Hepatocyte growth factor receptor (c-MET) is a tyrosine kinase
receptor associated in cancer with high migration, invasion and
angiogenesis ratios [32]. Gene ampliﬁcation and mutation on c-
MET is infrequent [33]; however, c-MET is overexpressed in around
80% of HNSCCs [34]. Furthermore, mutations on c-MET were asso-
ciated with lower development of distant metastasis in patients
treated with chemoradiotherapy [35].
Cyclin D1 encoded by CCND1 is present in multiple neoplasms.
It has been reported that CCND1 ampliﬁcation and overexpression
are associated with poor prognosis, cisplatin resistance, EGFR-in-
hibitor resistance [36,37] and nodal metastasis [38].
Lui et al. showed that mutations on a catalytic subunit of PI3K
(PI3KCA) sensitise tumours to an mTOR/PI3K inhibitor, and thus
may serve as predictive biomarkers for treatment selection [39].
New discoveries involving tumour suppressor genes appear to
provide an opportunity for target therapies. TP53 is the most com-
monly mutated gene and is ampliﬁed in 5% of HNSCC cases [20,21].
The primary mutations of TP53 are missense mutations or non-
sense mutations that create a stop codon resulting in a truncated
protein and leading to a loss of function [40]. In HNSCC, only
TP53 nonsense mutations that produced a truncated protein were
statistically signiﬁcant as prognostic factors [41]. Other TP53muta-
tions were not associated with poor outcome [42].
In HNSCC, NOTCH1 is considered to be a tumour suppressor
gene because of the lack of mutational hotspots and the high pro-
portion of nonsense mutations [20,21]. Mutations on NOTCH1
appeared in 43% of Chinese HNSCC population and correlated with
lymph-node metastasis and poor outcome [43]. Moreover, down-
stream Notch effectors were overexpressed in 32% of patients with
HNSCC [44]. All this indicates the potential therapeutic target of
Notch pathway in a subset of HNSCC.
There are other biomarkers based on viral aetiology. This is the
case of human papillomavirus (HPV) and Epstein–Barr virus (EBV).
The presence of HPV is a prognostic biomarker associated with bet-
ter outcome in locally advanced oropharyngeal cancers, with a 40–
80% reduction in death after treatment [45–48]. It has been report-
ed that HPV infection indirectly produces an increase of p16INK4A
expression [49–51]; as a result, p16INK4A is considered a surrogate
marker for HPV in oropharyngeal cancers [52–55]. HPV-negative
tumours bear more EGFR alterations [56] and overexpression of
total and phosphorylated EGFR protein [57]. Thus, new anti-EGFR
treatments could be of interest in the management of HPV-nega-
tive tumours.
DNA fragments from EBV detected by real-time quantitative
PCR in cell-free plasma are considered a prognostic biomarker for
nasopharyngeal carcinoma. High levels of EBV DNA were associat-
ed with advanced disease stage and poor outcome [58–60].
Furthermore, high levels of EBV DNA are a poor prognostic biomak-
er after radiotherapy, chemoradiotherapy and chemotherapy fol-
lowed by radiotherapy with or without concurrent chemotherapy
[61,62].Targeted treatments in HNSCC
With the identiﬁcation of common genetic aberrations and
altered signalling pathways in HNSCC, treatment of the disease is
evolving with the development of new drugs designed to target
crucial receptors and signalling pathways involved in carcino-
genesis. The role of EGFR (ErbB1/HER1) and its associated path-
ways, such as the MAPK pathway (Fig. 1), have been extensively
studied in HNSCC. EGFR belongs to the ErbB family of receptor tyr-
osine kinases, which also includes ErbB2 (HER2 or Neu), ErbB3
(HER3) and ErbB4 (HER4) [5,6]. In general, EGFR-targeted therapies
Fig. 1. EGFR signalling pathways. Epidermal growth factor receptor and ErbB family
downstream signalling pathways potentially involved in squamous cell carcinomas
of the head and neck. Downstream pathways activated by dimerisation and
activation of the EGFR.
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and angiogenesis as well as acting synergistically with chemora-
diation therapies [7]. It is postulated that EGFR-targeted agents
may achieve this synergistic effect by upregulating cyclin-depen-
dent kinase inhibitors such as p27, resulting in the arrest of the cell
cycle in the G1 phase [63]. EGFR is a 170 kd transmembrane glyco-
protein that includes an extracellular ligand-binding domain,
transmembrane domain and a tyrosine kinase active site within
its intracellular domain [64]. Consequently, there are 2 potential
sites for EGFR inhibitors to target. This discovery led to the devel-
opment of monoclonal antibodies to target the EGFR extracellular
ligand-binding domain and tyrosine kinase inhibitors which target
the EGFR tyrosine kinase intracellular domain.Table 2
EGFR inhibitors for the treatment of head and neck squamous cell carcinoma.
Agent Mechanism/target/binding
Panitumumab Fully human anti-EGFR mAb
Nimotuzumab Humanised anti-EGFR mAb
Zalutumumab Fully human anti-EGFR mAb
Geﬁtinib Reversible/small-molecule EGFR TKI
Erlotinib Reversible/small-molecule EGFR TKI
Lapatinib Reversible/small-molecule EGFR/ErbB2 TKI
Dacomitinib
(PF-00299804)
Irreversible/small-molecule pan-HER TKI
Afatinib (BIBW 2992) Irreversible/small-molecule ErbB family inhibitor
EGFR = epidermal growth factor receptor, TKI = tyrosine kinase inhibitor.
mAb = monoclonal antibody.Monoclonal antibody inhibitors to treat HNSCC
EGFR-targeted monoclonal antibody therapies have also been
investigated for treatment of patients with locoregionally
advanced disease. Cetuximab (Erbitux, Merck; Darmstadt,
Germany) is now approved for use in combination with radio-
therapy in patients with unresectable, locoregionally advanced
HNSCC. This approval was based on the phase III study by
Bonner et al. in which signiﬁcant improvement in overall survival
was observed for cetuximab plus radiotherapy versus radiotherapy
alone [65]. However, one of the main criticisms of the Bonner et al.
study was that the standard of care, cisplatin-based chemoradio-
therapy, was not included as a comparator arm. Consequently, it
is difﬁcult to determine whether cetuximab in combination with
radiotherapy is superior in terms of efﬁcacy. Recently, a study in
locoregionally advanced HNSCC has concluded that platinum-
based chemoradiotherapy is superior to cetuximab, used alone or
in combination with chemotherapy [66].
In patients with recurrent/metastatic HNSCC, the use of cetux-
imab, alone and in combination with platinum-based therapy,
has been encouraging, leading to improved outcomes in this
patient group [67–69] including in the ﬁrst-line setting [70,71].Indeed, as a result of clinical data, cetuximab is currently approved
for use (i) in Europe and the United States as a monotherapy in
platinum-refractory recurrent disease [68,72,73]; and (ii) in the
US combination with platinum (carboplatin or cisplatin) and 5-
ﬂuorouracil, as ﬁrst-line therapy in recurrent/metastatic disease
[8,68,71,72].
In HNSCC, several other treatments based on monoclonal
antibodies have reached phase III of development, including
panitumumab (Vectibix, Amgen; Thousand Oaks, CA, USA),
nimotuzumab (YM Biosciences; Ontario, Canada) and
zalutumumab (HuMax-EGFr, Genmab, Copenhagen, Denmark)
[7]. Panitumumab is a fully human anti-EGFR monoclonal antibody
that has recently been shown to extend progression-free survival
(but not overall survival) when combined with cisplatin/5-ﬂu-
ouracil in unselected patients with recurrent or metastatic
HNSCC (SPECTRUM trial) [74]. In addition, zalutumumab, also a
fully human monoclonal antibody, has been shown to signiﬁcantly
improve progression-free survival (but not overall survival) versus
best supportive care [75].
Tyrosine kinase inhibitors to treat HNSCC
Tyrosine kinases represent an excellent target for the develop-
ment of cancer drugs, and consequently, multiple tyrosine kinase
inhibitors have now been identiﬁed for potential use in HNSCC
(Table 2). All the tyrosine kinase inhibitors that are being investi-
gated in HNSCC target EGFR, including geﬁtinib (Iressa,
AstraZeneca; Wilmington, DE) and erlotinib (Tarceva, Genentech;
South San Francisco, CA) (Table 2), with some agents also now tar-
geting multiple ErbB family members, including lapatinib (Tykerb,
GlaxoSmithKline; Research Triangle Park, NC, USA), afatinib
(GIOTRIF/GILOTRIF, Boehringer Ingelheim, Germany) and dacomi-
tinib (Pﬁzer, Sandwich, Kent, UK). In addition to the newer agents,
dacomitinib and afatinib bind to the EGFR tyrosine kinase irre-
versibly rather than reversibly, as is the case with geﬁtinib, erloti-
nib and lapatinib.
Investigation of erlotinib and geﬁtinib in recurrent or metastatic
HNSCC has yielded somewhat disappointing results, with overall
response rates of 1.4–10.6% [76–78]. Furthermore, a phase III trial
has compared weekly intravenous methotrexate with geﬁtinib in a
heavily pre-treated population [79]. Geﬁtinib almost doubled the
objective response rate versus methotrexate (7.6% versus 3.9%),
although no improvement in overall survival was observed [79].
These data are encouraging since objective responses to second-
line cytotoxic chemotherapy after failure of ﬁrst-line chemother-
apy are unusual. Furthermore, there is no evidence that second-
line treatment prolongs survival. These data suggest that targeted
therapies may be a valuable addition to the treatment options in
this setting.
Lapatinib has been investigated in a phase II trial in combina-
tion with chemoradiation versus chemoradiation alone in locore-
gionally advanced HNSCC. The study showed an overall response
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6 months after completion of chemoradiotherapy [80]. However,
no signiﬁcant activity of lapatinib has been demonstrated in
patients with recurrent or metastatic HNSCC [81].
The irreversible tyrosine kinase inhibitor of EGFR, dacomitinib,
has been recently evaluated in a phase II trial in platinum-refracto-
ry patients with recurrent and/or metastatic squamous cell carci-
noma of the head and neck [82]. The study performed with 48
patients showed stable disease in 31 patients (65%) and disease
progression in 6 patients (13%), while 10 patients (20.8%) present-
ed partial response. The median progression-free survival was
3.9 months and overall survival was 6.6 months. These ﬁndings
may be veriﬁed with phase III clinical trials in order to compare
dacomitinib with other chemotherapies.Resistance to EGFR-targeted therapies
A crucial handicap for the newly available EGFR-targeted thera-
pies, including both monoclonal antibodies and tyrosine kinase
inhibitors, is resistance [83]. One of the main mechanisms of resis-
tance in HNSCC is the mutant type-III variant of EGFR (EGFRvIII)
[83,84]. This variant is characterised by an in-frame deletion of
exons 2 through 7 in the extracellular domain of EGFR (Fig. 2A).
This avoids the binding of ligands and consequently the activation
of the EGFR [83], and thereby it is associated with resistance to
EGFR monoclonal antibodies. The prevalence of EGFRvIII in
HNSCC is rather controversial. It has been reported that mutation
EGFRvIII was found in over 42% of 33 HNSCC tumors in conjunction
with wild-type EGFR [84]. In contrast, another study conducted
with 638 HNSCC samples showed that mutation is very rare in
HNSCC, as only 2 samples (0.31%) were positive for EGFRvIII [85].
Many EGFR mutations have been related to HNSCC [86–92]
(Fig. 2B). Some of them have also been involved in resistance toFig. 2. Diagram of EGFR mutations. (A) Mutant type-III variant of EGFR (EGFRvIII). (B) EGF
Cysteine-rich domain 1; L2: Large EGF-binding domain 2; CR2: Cysteine-rich domain 2.EGFR targeted therapies in HNSCC [93–95] (Fig. 2B). The resistance
to EGFR therapies could be different depending on the location of
the mutation. For instance, Kobayashi et al. showed that mutation
T790M, located in the catalytic region of the ATP-binding pocket,
will thus reduce the binding interaction with anti-EGFR tyrosine
kinase inhibitors [96].
Multiple other mechanisms of resistance to EGFR monoclonal
antibodies and tyrosine kinase inhibitors have been postulated
based on preclinical and clinical data [83,97]. In summary, the
mechanisms studied include reactivation of proangiogenic factors,
dysregulation of EGFR internalisation/degradation, oncogenic shift,
epithelial to mesenchymal shift, constitutive activation of EGFR
effector molecules and downstream signalling pathways and
increased expression of ErbB family growth factors [83,97].Afatinib as novel effective treatment against HNSCC
Afatinib (BIBW 2992) is an orally administered small molecule
that irreversibly blocks ErbB family receptors including EGFR,
ErbB2 and ErbB4 [5,6]. It is a new-generation ATP-competitive
anilinoquinazoline derivative that carries a reactive acrylamide
group [6] (Fig. 3) designed to bind covalently to active ErbB recep-
tor family members including EGFRwt, and mutant forms like
EGFRL858R, EGFRL858R/T790M (Fig. 2B) as well as HER2. When tested
in vitro, the IC50 values of afatinib to inhibit EGFRwt, EGFRL858R,
EGFRL858R/T790M and HER2 were: 0.5 nM, 0.4 nM, 10 nM and
14 nM, respectively [5]. Since afatinib binds irreversibly to ErbB
family receptors, the ATP binding site is permanently blocked
and downstream signalling cascades remain inhibited.
In vitro studies have demonstrated that afatinib signiﬁcantly
decreased the proliferation rate in a human hypopharyngeal
HNSCC cell line (FaDu) [98,99]. In addition, a dose-dependent
antiproliferative effect was observed with irreversible blockade ofR domains and mutations involved in HNSCC. L1: Large EGF-binding domain 1; CR1:
Citation number in [square brackets].
Fig. 3. Afatinib 2D molecular structure. IUPAC nomenclature: N-[4-[(3-Chloro-4-
ﬂuorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethy-
lamino)-2-butenamid.
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incubation with afatinib for 3 days slightly increased cell radiosen-
sitivity in vitro (p = 0.006) [99]. In vivo models generated with
FaDu cells showed an antiproliferative effect after daily oral
administration of afatinib and a signiﬁcant prolongation of tumour
growth delay (p < 0.0001) [98,99]. Afatinib has been evaluated in
phase I clinical trials where anti-tumour activity was observed in
patients with solid tumours [100,101].Afatinib in clinical trials
As part of the LUX clinical trial programme, afatinib is, or has
been, assessed in HNSCC in multiple clinical trials. A phase II trial
in which afatinib treatment was compared to cetuximab as a
monotherapy in 124 patients with platinum-refractory metastat-
ic/recurrent HNSCC has recently been completed and reported
[102,103]. In stage 1, the objective response rate was 16.1% and
6.5% by investigator review (p = 0.09) and median progression-free
survival was 16 weeks and 15 weeks (p = 0.93) for afatinib and
cetuximab, respectively [102]. In stage 2, when patients crossed
over to the other treatment arm, the disease control rates were
33% (afatinib as second treatment) and 19% (cetuximab as second
treatment) [103].
A 19-country phase III trial known as LUX-Head&Neck1
(NCT01345682) has recently been presented in ESMO [104]. The
study compared oral treatment with afatinib (322 patients) to
intravenous methotrexate (161 patients) with metastatic/recur-
rent HNSCC patients who have progressed after platinum-based
therapy. Afatinib improved progression-free survival (PFS) versus
methotrexate treatment (median 1.7 months) statistically sig-
niﬁcant (p = 0.03). Furthermore, secondary endpoints such as dis-
ease control rate were higher with afatinib versus methotrexate
(49.1% versus 38.5%; p = 0.035) and overall response rate (ORR)
was 10.2% versus 5.6% (p = 0.10). Tumour shrinkage from baseline
was observed in 34.8% of afatinib-treated patients compared with
22.4% of methotrexate-treated patients. However, afatinib did not
cause a statistically signiﬁcant improvement in overall survival
(OS) in comparison with methotrexate [104].
Other randomised trials assessing afatinib in the treatment of
head and neck cancer are ongoing. One clinical trial with a design
resembling that of LUX-Head&Neck1, called LUX-Head&Neck3
(NCT01856478), has also recently been initiated. Another phase
III trial, LUX-Head&Neck2 (NCT01345669), is a double-blind trial
in which afatinib is compared to placebo as adjuvant therapy after
chemoradiotherapy in 300 patients with unresected locoregional
HNSCC. A fourth trial, which is double-blind and placebo-con-
trolled, is investigating afatinib as a maintenance therapy after
post-operative radiochemotherapy, and results are expected in
2016 (NCT01523587).Discussion and conclusion
Treatments based on the inhibition of aberrant EGFR receptor
function have for a time been at the forefront of personalised ther-
apy for various neoplasms including breast, colon, lung, pancreatic
and stomach cancer. Multiple targeted drugs and monoclonal anti-
bodies such as cetuximab, panitumumab or trastuzumab are now
approved for several uses by health authorities worldwide.
Anti-EGFR drugs have been established as a novel and effective
tool to manage HNSCC. Thus, in the era of genomics, the medical
community now requires effective biomarkers to predict response
to these treatments. Overexpression of EGFR is related to resis-
tance to these drugs [24,25], EGFR overexpression determined by
immunohistochemistry is not applied for diagnostic use due to a
lack of sensitivity and speciﬁcity on available antibodies.
Therefore, mutations on EGFR have been more accepted in routine
clinical practice [28]. With the exception of EGFRvIII, this has
recently reported to be very rare ﬁnding in HNSCC [85].
Recently, some researchers have defended the notion that HPV
is a cause for some carcinomas. While the presence of HPV has
been demonstrated in a subset of patients with oropharyngeal can-
cer [45,105], the role of HPV in other cases of HNSCC has not yet
been clearly demonstrated [106,107]. In addition, the methodology
that should be used to determine HPV is disputed [23].
Subsequently, p16 (CDKN2A) appeared as a surrogate biomarker
for HPV status [51] and p16 was validated in a retrospective study
(RTOG 0129) [45]. Moreover, p16 was used in the SPECTRUM and
EXTREME trials’ analyses as a biomarker for HPV [74,108].
However, the cutoff point used in the assignment of positive cases
of p16 immunostaining was >10% in the SPECTRUM study versus
>70% in the EXTREME study; in addition, p16 determination by
immunohistochemistry is still controversial [23]. Furthermore,
both studies lacked a representative p16-positive sample size in
each treatment arm [74,108]. Accordingly, HPV predictive power
of anti-EGFR therapy response is unclear. In the SPECTRUM trial,
p16-positive patients presented longer OS, although p16-negative
patients improved overall and in terms of PFS after addition of
panitumumab [74]. In the EXTREME trial, as in the SPECTRUM trial,
p16 and HPV were prognostic markers in HNSCC, but the efﬁcacy
of chemotherapy plus cetuximab over chemotherapy alone was
independent of p16 or HPV status [108]. Consequently, to elucidate
the power of HPV or its surrogate marker p16 to act as biomarkers
requires a thorough study.
Moreover, other anti-EGFR therapies based on tyrosine kinase
inhibitors have been designed to bind covalently and irreversibly
to their targets. Covalent binding is thought to offer greater effec-
tiveness through longer binding time [109]. This is the case of afa-
tinib and dacomitinib. Phase II trials with dacomitinib involving
platinum-failed patients with recurrent-metastatic HNSCC showed
promising results. Nevertheless, 80% statistical power to obtain
65% of ORR resulted in 78% of stable disease or progression com-
pared to 20.8% presenting partial response [82]. Therefore, these
results may be validated in future phase III clinical trials to com-
pare the efﬁcacy of dacomitinib with other chemotherapies.
Afatinib is being investigated for several different types of can-
cer. Indeed, afatinib is now approved in many countries for the
treatment of patients with locally advanced or metastatic non-s-
mall cell lung cancer with EGFRmutation [110,111]. In HNSCC, afa-
tinib has demonstrated anti-proliferative activity in preclinical
studies and encouraging phase II clinical data versus cetuximab.
Further evaluation of afatinib in HNSCC as part of a phase III trial
has showed not only a signiﬁcant improvement in PFS but also in
tumour shrinkage, higher response rate and increased disease con-
trol rate versus methotrexate [104]. Other ongoing trials are eager-
ly awaited. The results of these trials will help us to understand the
place of afatinib in the HNSCC treatment armamentarium.
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